Zacharoula Sidiropoulou, Senior Consultant Breast Surgical Oncologist at Hospital São Francisco Xavier, shared a post on LinkedIn:
“We did it! Our Breast Unit at ULS Lisboa Ocidental has performed its first endoscopic mastectomy, adopting a revolutionary technique that is transforming breast cancer patient care globally.
We’re witnessing a remarkable convergence of advanced surgical techniques and personalized medicine that is delivering unprecedented patient outcomes. Recent research shows how endoscopic mastectomy, combined with genomic-guided decision-making, represents the future of individualized breast cancer care.
Personalized Surgical Oncology and Endoscopic Excellence: 2025 Evidence
A comprehensive meta-analysis of 2,612 patients shows:
- Oncological Safety: Equivalent cancer outcomes versus conventional surgery (52-month follow-up)
Superior Aesthetics: 88% improved cosmetic satisfaction (OR = 1.88; P = 0.020) - Reduced Complications: 81% decrease in postoperative necrosis with single-incision technique
- Precision Delivery: 4 cm incisions enable surgical precision
Our achievement positions ULS Lisboa Ocidental at the forefront of breast surgical innovation, aligning us with leading national and international centers in advancing minimally invasive oncological surgery.
This milestone represents our commitment to:
- Evidence-based surgical innovation
- Patient-centered personalized care
- Integration of cutting-edge technologies
- Superior aesthetic and functional outcomes
Future Vision
Next-generation sequencing for intraoperative genomic profiling
Advanced AI algorithms for surgical outcome prediction
Expanded applications across diverse patient populations
The Bottom Line
This achievement marks a new era for our patients: precision medicine defines surgical excellence.
At ULS Lisboa Ocidental, we’re not just adopting innovative techniques; we’re participating to co-create the future of personalized breast cancer care.
Every surgical decision needs to be tailored to each patient’s unique tumor biology, risk profile, and genomic fingerprint, ensuring optimal outcomes with minimal invasiveness.
Congratulations to our entire Breast team for this remarkable achievement! Guys, we have just started!
A hudge thank you to Gauthier Rathat and his team for the training, support and friendship provided!
A hudge thank you to Nelson Amado and Applied Medical for supporting us!”
You Can Also Read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
